Remnant cholesterol, preinflammatory state and chronic kidney disease: association and mediation analyses.

Publisher: Informa Healthcare Country of Publication: England NLM ID: 8701128 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-6049 (Electronic) Linking ISSN: 0886022X NLM ISO Abbreviation: Ren Fail Subsets: MEDLINE

Publication: London : Informa Healthcare
Original Publication: New York, N.Y. : M. Dekker, c1987-

Renal Insufficiency, Chronic*/blood ; Renal Insufficiency, Chronic*/complications ; Cholesterol*/blood ; C-Reactive Protein*/analysis ; Inflammation*/blood ; Nutrition Surveys*; China/epidemiology ; Biomarkers/blood ; Triglycerides/blood ; Humans ; Male ; Female ; Middle Aged ; Adult ; Cross-Sectional Studies ; Mediation Analysis ; Glomerular Filtration Rate ; Logistic Models ; Risk Factors ; Aged

Blood lipid management is a key approach in the prevention of chronic kidney disease (CKD). Remnant cholesterol (RC) plays an important role in the development of multiple diseases via chronic inflammation. The aim of our study was to determine the relationship between RC and CKD and explore the role of inflammation in this relationship. The 7696 subjects from the Chinese Health and Nutrition Survey were divided into four subgroups according to the quartile of RC. The estimated glomerular filtration rate was calculated using the CKD Epidemiology Collaboration equation. Fasting RC was calculated as total cholesterol minus low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. Logistic regression analysis was employed to evaluate the relationships between RC and CKD. Mediation analysis was undertaken to identify potential mediators of high-sensitivity C-reactive protein (hs-CRP) and white blood cells (WBCs). Of all participants, the mean age was 51 years, and the male accounted for 47.8%. The multivariable-adjusted odds ratios (95% CIs) for the highest versus lowest quartile of remnant cholesterol were 1.40 (1.10-1.78, p for trend = 0.006) for CKD. RC and preinflammatory markers have combined effect on CKD. The preinflammatory state, presented by increased hs-CRP or WBCs, partially mediated the association between RC and CKD with proportion of 10.14% (p = 0.002) and 11.65% (p = 0.012), respectively. In conclusion, this study suggested a positive relationship between RC and CKD, which was partially mediated by preinflammatory state. These findings highlight the importance of RC and inflammation in renal dysfunction.IMPACT STATEMENTWhat is already known on this subject?: Dyslipidemia plays an important role in the development of chronic kidney disease (CKD). Remnant cholesterol (RC), as a triglyceride-rich particle, can contribute to target organ damage, primarily through inflammatory pathways. However, the relationship between RC and CKD in the community-dwelling population, particularly the role of inflammation, is not yet fully understood.What do the results of this study add?: This study shows that RC was significantly associated with CKD. RC and preinflammatory status exhibit a combined effect on CKD. Preinflammatory state, presented by increased high-sensitivity C-reactive protein or white blood cells, partially mediated the association between RC and CKD.What are the implications of these findings for clinical practice and/or further research?: The study provides us with a better understanding of the role of RC and inflammation in kidney dysfunction and raises the awareness of RC in the management of CKD.

J Clin Med. 2023 Jun 02;12(11):. (PMID: 37298013)
Cell Metab. 2021 Oct 5;33(10):1911-1925. (PMID: 34562355)
Inflammation. 2012 Jun;35(3):1094-101. (PMID: 22160841)
Lipids Health Dis. 2024 Jan 4;23(1):2. (PMID: 38178232)
Kidney Int. 2019 Mar;95(3):577-589. (PMID: 30639234)
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. (PMID: 34964875)
Am J Kidney Dis. 2010 Jul;56(1):32-8. (PMID: 20416999)
Clin Exp Nephrol. 2014 Apr;18(2):243-6. (PMID: 24052157)
J Clin Invest. 2019 Jul 22;129(8):3387-3400. (PMID: 31329164)
Lancet. 2020 Feb 29;395(10225):709-733. (PMID: 32061315)
Signal Transduct Target Ther. 2022 Jun 9;7(1):182. (PMID: 35680856)
J Diabetes. 2020 Dec;12(12):870-880. (PMID: 32500969)
Int J Mol Sci. 2022 Apr 13;23(8):. (PMID: 35457118)
Cell Death Dis. 2020 Oct 24;11(10):914. (PMID: 33099578)
Circulation. 2013 Sep 17;128(12):1298-309. (PMID: 23926208)
Diabetes Res Clin Pract. 2024 Apr;210:111639. (PMID: 38548106)
Cardiovasc Res. 2022 Feb 21;118(3):716-731. (PMID: 33483737)
Atherosclerosis. 2023 Aug;379:117141. (PMID: 37217436)
Obes Rev. 2014 Jan;15 Suppl 1:2-7. (PMID: 24341753)
J Diabetes Res. 2020 Sep 28;2020:3613041. (PMID: 33062710)
Am J Kidney Dis. 2018 Feb;71(2):166-172. (PMID: 28754456)
Acta Diabetol. 2021 Dec;58(12):1615-1625. (PMID: 34181081)
J Clin Endocrinol Metab. 2018 Dec 1;103(12):4491-4500. (PMID: 30085243)
Arterioscler Thromb Vasc Biol. 2016 Nov;36(11):2133-2135. (PMID: 27784698)
Inflammation. 2015;38(3):959-71. (PMID: 25387652)
Expert Opin Ther Targets. 2019 Jul;23(7):619-630. (PMID: 31100024)
J Diabetes Investig. 2022 May;13(5):868-877. (PMID: 34902230)
J Clin Lipidol. 2021 Jan-Feb;15(1):3-17. (PMID: 33589093)
Circ Cardiovasc Imaging. 2021 Apr;14(4):e010953. (PMID: 33832329)
Atherosclerosis. 2020 May;300:19-25. (PMID: 32276134)
Signal Transduct Target Ther. 2023 Mar 17;8(1):129. (PMID: 36932062)
Am J Physiol Endocrinol Metab. 2023 Jan 1;324(1):E24-E41. (PMID: 36383637)
BMC Nephrol. 2021 Jan 20;22(1):35. (PMID: 33472594)
Front Endocrinol (Lausanne). 2023 Jun 21;14:1189574. (PMID: 37415665)
Int J Environ Res Public Health. 2014 Jul 29;11(8):7622-35. (PMID: 25075881)
Curr Opin Lipidol. 2017 Aug;28(4):300-307. (PMID: 28548974)
Atherosclerosis. 2008 Mar;197(1):154-8. (PMID: 17462654)
J Diabetes Complications. 2023 Sep;37(9):108585. (PMID: 37633073)
Ren Fail. 2018 Nov;40(1):43-50. (PMID: 29304720)
Endocrine. 2022 May;76(2):312-323. (PMID: 35239125)
Am J Kidney Dis. 2019 Jun;73(6):827-836. (PMID: 30686529)
J Am Soc Nephrol. 2017 May;28(5):1534-1551. (PMID: 27932476)
Clin J Am Soc Nephrol. 2014 Jul;9(7):1190-8. (PMID: 24832097)
Nat Rev Nephrol. 2023 Oct;19(10):629-645. (PMID: 37500941)
Nat Rev Nephrol. 2021 Aug;17(8):528-542. (PMID: 33972752)
Cardiol J. 2022;29(5):782-790. (PMID: 35373329)
Curr Vasc Pharmacol. 2017;15(2):144-151. (PMID: 27697068)
Acta Diabetol. 2024 Jun;61(6):735-743. (PMID: 38436703)

Keywords: Chronic kidney disease; inflammation; mediation; remnant cholesterol

97C5T2UQ7J (Cholesterol)
9007-41-4 (C-Reactive Protein)
0 (Biomarkers)
0 (Triglycerides)

Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240614

20260130

PMC11168229

10.1080/0886022X.2024.2361094

38856016